These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 24657802)

  • 1. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
    Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
    J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
    Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
    J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
    Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
    BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
    Mazza P; Moran GW; Li G; Robins DJ; Matulay JT; Herr HW; Decastro GJ; McKiernan JM; Anderson CB
    J Urol; 2018 Nov; 200(5):1005-1013. PubMed ID: 29787740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
    Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
    J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
    Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
    BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
    Izawa JI; Chin JL; Winquist E
    Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.